News Articles

Browse our entire archive of news articles, spotlight interviews, and other editorial pieces in one place.

Filters
Clear all
Showing 0 of 100
Keyword Search
Open Arrow
Article Type
Open Arrow
Company
Open Arrow
Clear all
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Filters
Tag
Close Icon

Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs

News
January 8, 2023
Cybin Inc.

FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023

News
January 6, 2023
FSD Pharma

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

News
January 5, 2023
Clearmind Medicine

Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy

News
January 5, 2023
Tryp Therapeutics

PsyBio Announces Closing of First Tranche of Private Placement and Provides Corporate Update

News
January 5, 2023
PsyBio Therapeutics

Universal Ibogaine Highlights 2022 Accomplishments

News
January 4, 2023
Universal Ibogaine

Reunion Neuroscience Inc. Provides 2023 Corporate Update

News
January 4, 2023
Reunion Neuroscience

Israel-Based Clearmind Medicine Inc. CEO Discusses the Potential of Psychedelics for Addiction Treatment in Audio Interview with SmallCapVoice.com

News
January 4, 2023
Clearmind Medicine

Numinus to Host Q1 2023 Results Conference Call on January 16, 2023

News
January 4, 2023
Numinus

Blackhawk's Shareholders Vote in Favour of Plan of Arrangement to Spin-out its Subsidiary, 1286409 B.C. Ltd. (Mindbio Therapeutics Corp.) to Form an Independent Listed Company

News
January 3, 2023
MindBio Therapeutics

Tryp Therapeutics and Massachusetts General Hospital Sign Letter of Intent for Clinical Study Investigating the Use of Psilocybin-Assisted Psychotherapy for the Treatment of Patients Suffering From Irritable Bowel Syndrome (IBS)

News
January 3, 2023
Tryp Therapeutics

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program

News
January 3, 2023
Algernon Pharmaceuticals

Clearmind Medicine Announces Shareholders Meeting Results

News
December 29, 2022
Clearmind Medicine

Biomind Labs Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease

News
December 28, 2022
Biomind Labs

Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

News
December 28, 2022
Clearmind Medicine

Psilocybin for Alcohol Dependence Trial by B.More Principal Investigator, Michael Bogenschutz, Recognized as Pivotal Psychedelic Breakthrough for 2022

News
December 23, 2022
B.More

Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial

News
December 23, 2022
Wellbeing Digital Sciences

Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003, a Novel Benzoate Formulation of 5-MeO-DMT, for Treatment Resistant Depression

News
December 22, 2022
Beckley Psytech

Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property

News
December 22, 2022
Small Pharma

Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute

News
December 21, 2022
Clearmind Medicine
No results found.
There are no results with this criteria. Try changing your search.
HomeNewsCompaniesSpotlightsSubscribe
Instagram
Twitter
RSS Feed
Email Us
©XXXX Psychedelic Finance. All rights reserved.
Privacy Policy
Core One Labs Inc.
Creso Pharma
Cybin Inc.
Enveric Biosciences
Field Trip Health
Filament Health
Havn Life
Levitee Labs
MINDCURE
Mydecine Innovations Group
NeonMind Biosciences Inc.
Novamind Inc.
Numinus
Optimi Health
Pharmather
PsyBio Therapeutics
Psyched Wellness
Psyence Group
Pure Extracts Corp
Silo Wellness
The Good Shroom Co
Tryp Therapeutics
Wesana Health
Aja Ventures
Albert Labs
Algernon Pharmaceuticals
Apex Labs Ltd.
B.More
Beckley Foundation
BetterLife Pharma
Bexson Biomedical
Biomind Labs
Bionomics
Braxia Scientific Corp.
Bright Minds
CB Therapeutics
Ceruvia Lifesciences
Clairvoyant Therapeutics
Clearmind Medicine
Clexio Biosciences
Cognetivity Neurosciences
Cube Psytech
Delic
Delix Therapeutics
Diamond Therapeutics
Ehave
FSD Pharma
Fluence
Freedom to Operate
HMNC Brain Health
Horizons ETFs Management Inc.
Incannex Healthcare
IntelGenx
Irwin Naturals
Ixtlan Bioscience
Johns Hopkins Medicine
MYND Diagnostics
Mind Medicine (MindMed)
MindBio Therapeutics
Mindset Pharma
Mycotopia Therapies
Mycrodose Therapeutics
Neural Therapeutics
Ninnion
Nirvana Life Sciences
Nova Mentis Life Science
Origin Therapeutics
Osmind
Pasithea Therapeutics
Pharmala Biotech Holdings
Psilera
Psilotec Health Solutions
PsyRx
Psylo
Quantified Citizen
Reunion Neuroscience
Revitalist Lifestyle and Wellness
Revive Therapeutics
Seelos Therapeutics
Small Pharma
Telescope Innovations
TheraPsil
TripSitter
Universal Ibogaine
Wellbeing Digital Sciences
Woke Pharmaceuticals
Woven Science
ATAI Life Sciences
Awakn Life Sciences
Beckley Psytech
Compass Pathways
Doseology Sciences
EI.ventures
Eleusis
Entheon Biomedical
Gilgamesh Pharmaceuticals
GoodCap Wellness
Lobe Sciences
Lophora
MAPS